Nov 14 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX
* Successfully completes Phase 2A clinical trial in bone marrow lesions
* Phase 2A clinical trial in bone marrow lesions (bone bruising) met its primary endpoint of safety & tolerability
* Secondary endpoint was met and showed a statistically significant reduction in bone marrow lesion volume